ASPCF News and Press, Acerus Pharmaceuticals Corp From 07/19/19

Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP, OTCQB:ASPCF) today announced that it has entered into a US$5 million subordinated secured term loan facility (“the Loan”) with First Generation Capital Inc. (“First Genera...

Acerus Pharmaceuticals Corporation (TSX: ASP, OTCQB: ASPCF) (“Acerus” or the “Company”) announced today an update relative to the Company’s NATESTO ® business. The Company announced that Hyundai Pharm Co., Ltd. (“Hyundai”) has officially ...

Acerus Pharmaceuticals Corporation (TSX: ASP, OTCQB: ASPCF) (“Acerus” or the “Company”) announced today the acceptance of a new manuscript to the Journal of the Endocrine Society, describing how NATESTO ® achieves similar symptom improvement, regardless of th...

Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB: ASPCF) (“Acerus” or the “Company”) today announced that it entered into an amended agreement related to its existing credit facility with SWK Funding LLC (“SWK”). The nature of the amendment is t...

Acerus Announces Voting Results for the 2019 Annual Meeting Canada NewsWire TORONTO, June 27, 2019 TORONTO , June 27, 2019 /CNW/ - Acerus Pharmaceuticals Corporation (" Acerus ") (TSX:ASP) today announced the voting results from its annual meeting of shareholders held on ...

Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) (“Acerus” or the “Company”) today announced that Health Canada has completed the initial screening process for the previously announced New Drug Submission (“NDS”) for avanafil. The dossier is ...

Play Video It’s no secret that the healthcare systems in Canada and the US have for years been compared to one another and, as neighboring countries, it’s impossible not to pin the two against each ot...

Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB: ASPCF) (“Acerus” or the “Company”) today announced that it has reached a mutual agreement with Innovus Pharmaceuticals, Inc. (OTCQB: INNV) (“Innovus Pharma”), a California-based specialty ...

Acerus Pharmaceuticals Corporation (“Acerus” or “the Company”) (TSX:ASP; OTCQB:ASPCF) announced today that it has signed a patent license agreement (the “PLA”) with the University of Texas at Austin for technology related to the nasal administra...

With the 2019 Bloom Burton & Co. Healthcare Investor Conference (BBHIC) officially behind us for another year, one thing was made very clear at this year’s two-day event based on the attendance: sentiment in the life science sectors is stronger than ever. In his opening r...